BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23032071)

  • 1. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
    Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
    Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
    Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
    Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
    Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
    Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
    McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
    Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
    Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
    Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
    Ray LA; Hutchison KE
    Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
    Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues.
    Ray LA; Courtney KE; Hutchison KE; Mackillop J; Galvan A; Ghahremani DG
    Alcohol Clin Exp Res; 2014 Jan; 38(1):78-89. PubMed ID: 23876228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
    Schacht JP; Voronin KE; Randall PK; Anton RF
    Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
    Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
    Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
    Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
    Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
    Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
    Kranzler HR; Armeli S; Covault J; Tennen H
    Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects.
    Bach P; Vollsta Dt-Klein S; Kirsch M; Hoffmann S; Jorde A; Frank J; Charlet K; Beck A; Heinz A; Walter H; Sommer WH; Spanagel R; Rietschel M; Kiefer F
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1128-35. PubMed ID: 25937240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
    Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
    Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
    Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
    Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent.
    Lim AC; Ghahremani DG; Grodin EN; Green R; Bujarski S; Hartwell EE; Courtney KE; Hutchison K; Miotto K; Ray LA
    Drug Alcohol Depend; 2019 Jul; 200():181-190. PubMed ID: 31160146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.